Endocrinology, diabetes & metabolism · 2026
Association Between Impaired Fasting Glucose and Adverse Outcomes in Patients Treated With Peritoneal Dialysis: A Retrospective Study From Southern China.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hu Qinghua, Luo Qimei, Ai Jun, Chen Jiayi, Pan Jianyi, Chen Jinzhong, Zhang Jun, Dou Xianrui
Аннотация
AIM: The aim of this research was to explore the relationship between impaired fasting glucose (IFG) and adverse clinical outcomes in a southern Chinese population receiving peritoneal dialysis (PD) therapy.
METHODS: Participants who underwent PD therapy for > 3 months during January 1, 2004 to July 27, 2021, across four centers were included. Baseline data were collected in the initial 3 months of PD therapy. We defined IFG using World Health Organization criteria (IFG-WHO: 6.1-6.9 mmol/L). The adverse outcomes included all-cause mortality, cardiovascular mortality and cardiovascular events. Kaplan-Meier survival analyses and Cox regression models were utilized to assess the associations between IFG and adverse outcomes.
RESULTS: A total of 2345 PD patients were included, with 666 (28.4%) diagnosed with diabetes and 209 (8.9%) with IFG. Over an average follow-up duration of 32 months (25th-75th, 15-54), 276 (11.8%) deaths occurred, including 186 (7.9%) cardiovascular mortality, and 356 (15.2%) cardiovascular events were documented. Kaplan-Meier survival curves showed that patients with IFG had a significantly higher risk of cardiovascular mortality than those with normoglycemia. Cox multivariate analysis showed that IFG was an independent risk factor for cardiovascular mortality (HR = 1.735; 95% CI: 1.023-2.944) after adjusting for confounders. No significant differences were observed in all-cause mortality or cardiovascular event risks between groups.
CONCLUSIONS: IFG was independently associated with increased cardiovascular mortality in PD patients. These findings highlight the need for glycemic monitoring in non-diabetic PD populations.
METHODS: Participants who underwent PD therapy for > 3 months during January 1, 2004 to July 27, 2021, across four centers were included. Baseline data were collected in the initial 3 months of PD therapy. We defined IFG using World Health Organization criteria (IFG-WHO: 6.1-6.9 mmol/L). The adverse outcomes included all-cause mortality, cardiovascular mortality and cardiovascular events. Kaplan-Meier survival analyses and Cox regression models were utilized to assess the associations between IFG and adverse outcomes.
RESULTS: A total of 2345 PD patients were included, with 666 (28.4%) diagnosed with diabetes and 209 (8.9%) with IFG. Over an average follow-up duration of 32 months (25th-75th, 15-54), 276 (11.8%) deaths occurred, including 186 (7.9%) cardiovascular mortality, and 356 (15.2%) cardiovascular events were documented. Kaplan-Meier survival curves showed that patients with IFG had a significantly higher risk of cardiovascular mortality than those with normoglycemia. Cox multivariate analysis showed that IFG was an independent risk factor for cardiovascular mortality (HR = 1.735; 95% CI: 1.023-2.944) after adjusting for confounders. No significant differences were observed in all-cause mortality or cardiovascular event risks between groups.
CONCLUSIONS: IFG was independently associated with increased cardiovascular mortality in PD patients. These findings highlight the need for glycemic monitoring in non-diabetic PD populations.